Drug Profile

ABT 418

Latest Information Update: 24 Jan 2013

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Abbott Laboratories
Class
Mechanism of Action Nicotinic receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Alzheimer's disease; Anxiety disorders; Attention-deficit hyperactivity disorder

Most Recent Events

17 Jan 2000 Investigation in Attention-deficit hyperactivity disorder in USA (Transdermal)
22 Jul 1997 Discontinued-II for Alzheimer's disease in USA (Unknown route)
22 Jul 1997 No-Development-Reported for Anxiety disorders in USA (Unknown route)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com